Do you want to link to this Amgen website and leave


Amgen Hong Kong takes no responsibility for, and exercises no control over, the organizations, views, or accuracy of the information contained on this server or site.


Amgen’s medicines treat serious illnesses and typically address diseases with a limited number of treatment options. With a presence in approximately 100 countries, we are proud to have reached millions of people with our products.


Products available in Hong Kong (Please consult physician for further information on prescription products):

  • kyprolis-trademark
  • mvasi
  • neulasta
  • neupogen
  • prolia
  • repatha_logo
  • vectibix
  • xgeva

Date of Approval: May 2021

Adverse event or side effect reporting

If you think you may have experienced an adverse event (‘side effect’) after taking or using an Amgen product
please call 800 961 142 , email:

Medical enquiries

If you want to contact Amgen for any of the following reasons:

  • you think there may be a defect or quality issue with the Amgen product you have received
  • you have a general medical information enquiry about your Amgen product
    Please call 800 961 142 or email:

Research and Development Strategy

Amgen has built an organization distinguished by world-class scientists with a talent for applying novel approaches to treat disease. Our R&D strategy aims to align and engage our talent, prioritize investments, and seize scientific opportunities.



Amgen has created a robust and differentiated pipeline, leveraging state-of-the-art science to create medicines for serious illnesses.